Chemotherapy and radiotherapy aim to destroy cancer cells by causing DNA double-strand breaks, but a signaling pathway called IKK/NF-κB activated by this damage can hinder the cell's death, limiting the treatments' success. Now, researchers at the Max Delbrück Center have identified two lead compounds, MW01 and MW05, that selectively inhibit the IKK/NF-κB pathway when triggered by DNA double-strand breaks, enhancing the potential for more promising cancer therapies.
NF-κB is a gene regulator family controlling various cellular processes, and IKK activates the IKK/NF-κB signaling pathway. Blocking IKK/NF-κB directly isn't feasible due to its vital functions. Identifying selective NF-κB inhibitors activated by DNA damage is challenging, as two enzymes (ATM and PARP1) initiate the signaling pathway during DNA double-strand breaks, and they must not be pharmacologically blocked due to their critical roles in biological emergency programs.
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
The team examined 32,000 substances and discovered MW01 and MW05 effectively block the signaling pathway only when triggered by DNA double-strand breaks. Surprisingly, they found the compounds bind to and deactivate kinases CLK2 and CLK4, which are necessary for signal transmission between ATM and IKK. CLK2 is often overexpressed in various cancers, suggesting it plays a role in tumorigenesis or cancer progression.
Experiments on osteosarcoma cells showed that MW01 and MW05 make cancer cells more sensitive to chemotherapy. After pretreatment with these compounds, more cancer cells died during subsequent genotoxic treatment. Initial toxicological tests in mice showed the substances were well-tolerated, with potential inhibitory effects on enzymes involved in tumor growth beyond the IKK/NF-κB signaling pathway.
While the findings, published in Cell Chemical Biology, show promise for more effective cancer therapies, further preclinical studies are required before the CLK inhibitors can be clinically approved. Although the road to approval may be lengthy, targeting the DNA damage response pathway presents a potential double whammy approach to cancer therapy, enhancing treatment success while inhibiting tumor growth processes.